

## 54gene Stakeholder Brief

CONFIDENTIAL  
Q2 2022 · ISSUE 06

# Q2 2022: Execution, Data, and Strategic Momentum.

*A quarterly update for investors and strategic stakeholders on operational performance, research progress, and forward outlook.*

---

### EXECUTIVE SUMMARY

---

## A Quarter of Deliberate Progress

Q2 2022 represented a period of significant operational and scientific advancement for 54gene. We deepened our data infrastructure, expanded our institutional partnerships, and maintained disciplined execution against our research and commercial roadmaps. This brief summarises the key developments, metrics, and milestones relevant to your continued understanding of our trajectory.

We continue to operate with a clear thesis: that the systematic underrepresentation of African genomic data in global biomedical research represents one of the most

consequential — and addressable — gaps in modern medicine. Our work this quarter moved us materially closer to being the institution that closes it.

---

#### QUARTER IN REVIEW

---

## Q2 Strategic Highlights

### **Biobank Expansion**

Biospecimen collection exceeded Q2 targets, with significant additions to our multi-ethnic African genomics dataset across three collection sites.

### **Commercial Partnership Progress**

MOU signed with a major West African hospital network, establishing a framework for longitudinal research collaboration and data access.

### **Scientific Output**

First internally-led pharmacogenomics manuscript submitted for peer review — a milestone in establishing 54gene's independent scientific credibility.

### **Infrastructure Investment**

Laboratory sequencing capacity increased by approximately 40% through targeted equipment investment, reducing per-sample processing costs.

---

## PERFORMANCE DATA

---

### Numbers & Stats — Q2 2022

Key operational and research metrics for the quarter. All figures are internal estimates; audited financials available on request.

**14K+**

SAMPLES ADDED  
THIS QUARTER

**3**

ACTIVE  
COLLECTION  
SITES

**40%**

INCREASE IN  
SEQUENCING  
CAPACITY

**2**

ETHICS  
APPROVALS  
SECURED

**1**

MANUSCRIPT  
SUBMITTED

**14**

NEW HIRES  
THIS QUARTER

---

## MILESTONE TRACKER

---

### Key Milestones — Q2 2022

**Hospital Network MOU:** Formal memorandum of understanding executed with a leading West African teaching hospital system, covering de-identified data access for three therapeutic research programmes including sickle cell disease, hypertension, and Type 2 diabetes.

---

**Advisory Board Constituted:** First formal meeting of our Scientific Advisory Board held — five internationally recognised genomics experts providing independent oversight and strategic guidance on our research portfolio.

---

**Ethics & Compliance:** IRB approval granted for two new research protocols. All active studies operating under current consent frameworks aligned with GDPR-equivalent data protection standards.

---

**Pipeline Upgrade Completed:** Internal bioinformatics pipeline upgraded, resulting in improved variant calling accuracy and a 40% increase in throughput — directly improving data quality for partner-facing outputs.

---

**Headcount Growth:** 14 net new hires in Q2 across scientific, technical, and commercial functions. Headcount now stands at [X] across Nigeria and the United States.

---

FORWARD OUTLOOK

---

## Q3 2022 Priorities & Anticipated Milestones

The following represents our current operational and strategic focus for the quarter ahead.

- 01 Third collection site activation** — expansion into a new geographic region will broaden ethnic and demographic diversity within the biobank, strengthening the commercial and scientific value of our dataset.
- 02 Pharmaceutical partnership pipeline** — we have two active conversations with global pharma partners regarding data access agreements. We anticipate one formal agreement to be executed before end of Q3.
- 03 Manuscript review and publication** — our Q2 submission is currently under peer review. Upon acceptance, this will represent 54gene's first independently authored publication in a high-impact journal.
- 04 Financial update** — Q2 management accounts will be shared with investors in the standard reporting pack by [date]. Q3 budget review is scheduled for [month] board call.

---

We remain committed to transparency and welcome questions between reporting cycles. Please reach out directly to our investor relations contact for any follow-up.

— *Dr. Abasi Ene-Obong, Founder & CEO*  
*54gene · Q2 2022 Stakeholder Brief*



Confidential — For Authorised Recipients Only · Q2 2022  
Investor Relations: [ir@54gene.com](mailto:ir@54gene.com)